{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:00:59Z","timestamp":1783418459708,"version":"3.54.6"},"reference-count":19,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T00:00:00Z","timestamp":1441152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Human papillomavirus (HPV) are firmly established as the principal causative agent for cervical carcinoma. Current vaccines may provide some protection for women from cervical carcinoma linked to HPV genotype 16 and 18. This may be the best vaccine for Western women, but the geographical variation in HPV distributions may not make it the most appropriate vaccine for China or Asia. This study provided an observational, retrospective, hospital-based cross-sectional study on the distribution of HPV genotypes among 5410 women with invasive cervical cancer (ICC) or cervical intraepithelial neoplasia (CIN). Overall, the positive rates of the four HPV types included in current prophylactic vaccines were counted, the two high-risk types (HPV-16 and -18) covered by current vaccines represented 66.9% of women with squamous cancer, 55.0% with adenocarcinoma, 64.9% with adenosquamous carcinoma and 77.4% of other type ICC, as well as 59.5% of CIN III, 45.0% of CIN II and 38.1% of CIN I cases. As expected, two low-risk types (HPV-6 and -11) included in the quadrivalent vaccine did not show good coverage data. Particularly worth mentioning is the fact that the addition of HPV-52 and -58 to the vaccine cocktail would increase cancer protection in our population, potentially preventing up to beyond 16% of squamous\/adenosquamous carcinoma and other type of cervical cancers, and 7.75% of adenocarcinomas. It might also potentially reduce the rate of CIN III by a further 28.6% and CIN II and I by a third. This study established the baseline for surveillance in Zhejiang  Province, and provides data for further vaccine designs: a quadrivalent HPV vaccine covering HPV-16\/-58\/-18\/-52, would be more welcome in our region in the forthcoming year compared to the currently available vaccine.<\/jats:p>","DOI":"10.3390\/ijerph120910794","type":"journal-article","created":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T03:10:43Z","timestamp":1441249843000},"page":"10794-10805","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Distribution of HPV Genotype in Invasive Cervical Carcinoma and Cervical Intraepithelial Neoplasia in Zhejiang Province, Southeast China: Establishing the Baseline for Surveillance"],"prefix":"10.3390","volume":"12","author":[{"given":"Xiao-Xian","family":"Xu","sequence":"first","affiliation":[{"name":"The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China"},{"name":"Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Song","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China"},{"name":"Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hui","family":"Yuan","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China"},{"name":"Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yu","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China"},{"name":"Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Mei","family":"Lou","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China"},{"name":"Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional survey","volume":"11","author":"Quint","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(05)67069-9","article-title":"Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: A pooled analysis","volume":"366","author":"Clifford","year":"2005","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: From basic studies to clinical application","volume":"2","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tao, P., Zheng, W., Wang, Y., and Bian, M. (2012). Sensitive HPV genotyping based on the flow-through hybridization and gene chip. J. Biomed. Biotechnol., 2012.","DOI":"10.1155\/2012\/938780"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1590\/S1677-5538.IBJU.2014.01.10","article-title":"Genital prevalence of HPV types and co-infection in men","volume":"40","author":"Freire","year":"2014","journal-title":"Int. Braz. J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ye, J., Cheng, X., Chen, X., Ye, F., L\u00fc, W., and Xie, X. (2010). Prevalence and risk profile of cervical human papillomavirus infection in Zhejiang Province, southeast China: A population-based study. Virol. J., 7.","DOI":"10.1186\/1743-422X-7-66"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/0008-5472.CAN-08-4192","article-title":"Detection of precancerous cervical lesions is differential by human papillomavirus type","volume":"69","author":"Safaeian","year":"2009","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Jaisamrarn, U., Castellsagu\u00e9, X., Garland, S.M., Naud, P., Palmroth, J., Del Rosario-Raymundo, M.R., Wheeler, C.M., Salmer\u00f3n, J., Chow, S.N., and Apter, D. (2013). Natural history of progression of HPV infection to cervical lesion or clearance: Analysis of the control arm of the large, randomised PATRICIA study. PLoS ONE, 8.","DOI":"10.1371\/annotation\/cea59317-929c-464a-b3f7-e095248f229a"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/IGC.0b013e31821dd3b2","article-title":"Prevalence of human papillomavirus infection in women in Portugal: The CLEOPATRE Portugal Study","volume":"21","author":"Pista","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_15","first-page":"467","article-title":"Role of the association of high-risk HPV identified by real-time PCR in cervical preneoplastic lesions","volume":"33","author":"Balbi","year":"2012","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1158\/1055-9965.EPI-06-0129","article-title":"Human papillomavirus infections with multiple types and risk of cervical neoplasia","volume":"15","author":"Trottier","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/jcp.2004.022863","article-title":"Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study","volume":"58","author":"Cuschieri","year":"2005","journal-title":"J. Clin. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.meegid.2013.11.002","article-title":"Genomic diversity of human papillomaviruses (HPV) and clinical implications: An overview in adulthood and childhood","volume":"21","author":"Mammas","year":"2014","journal-title":"Infect. Genet. Evol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nyg\u00e5rd, M., Hansen, B.T., Dillner, J., Munk, C., Oddsson, K., Tryggvadottir, L., Hortlund, M., Liaw, K.L., Dasbach, E.J., and Kj\u00e6r, S.K. (2014). Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: Establishing the baseline for surveillance. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088323"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/12\/9\/10794\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:47:52Z","timestamp":1760215672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/12\/9\/10794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,2]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9]]}},"alternative-id":["ijerph120910794"],"URL":"https:\/\/doi.org\/10.3390\/ijerph120910794","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,2]]}}}